Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Surprised you still say the science has only been positive. The facts tell a different story...no pharma interest, Amgen severed ties and and the only money the company can raise is on terrible terms. Berlin has done as good a job as he can with a clincial program that has not generated good enough data to hold commercial promise. We only have ourselves to blame. I wish I had seen the writing on the wall when ADURO shut down its LLM program. The market is valuing ADXS' science whether we like it or not.